Patent: 10,047,116
✉ Email this page to a colleague
Summary for Patent: 10,047,116
Title: | Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
Abstract: | The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method. |
Inventor(s): | Morein; Bror (Uppsala, SE), Berenjian; Saideh (Uppsala, SE), Hu; Kafei (Uppsala, SE) |
Assignee: | MX Adjuvac AB (Enkoping, SE) |
Application Number: | 14/349,142 |
Patent Claims: | see list of patent claims |
Details for Patent 10,047,116
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Seqirus Vaccines Limited | FLUVIRIN | influenza virus vaccine | Injection | 103837 | 11/03/1998 | ⤷ Try a Trial | 2040-01-30 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/09/1999 | ⤷ Try a Trial | 2040-01-30 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/23/1909 | ⤷ Try a Trial | 2040-01-30 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 05/09/2011 | ⤷ Try a Trial | 2040-01-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |